
Tuesday, June 08, 2021 2:30:27 PM
Mentioned: VBIV
Canada has become a destination for international collaborations and partnerships, as the long-standing reputation for the quality and caliber of research underway in Canadian SMEs, and research institutions drives awareness.
"The annual BIO convention is unique in that unlike other traditional trade shows, it is not companies selling products but rather countries, regions, and states competing to attract companies, talent and investment. This is a difficult competition during ordinary times, but the pandemic has heightened awareness globally of the value of developing domestic biotech innovation capacity. Accordingly, the competition amongst nations to attract ideas, companies and people is even more intense at this year's BIO. Importantly, with Acuitas' technology central to Pfizer's mRNA vaccine and the emergence over the course of the pandemic of AbCellera, Precision Nanosystems, VBI Vaccines, IMV Inc, and Medicago, Canadian companies and technologies have rightly attracted significant global attention. In this context, the BIO convention platform presents an important and timely opportunity to showcase Canadian companies, innovation and talent," commented Andrew Casey President and CEO BIOTECanada.
Canadian programming highlights include the following. Register here.
Wednesday June 910AM ET - Showcasing Canadian Biotechnology Innovation
A time to celebrate the remarkable scientific achievement for which the global biotech industry, the scientific community and regulators should be recognized. Incredible accomplishment of developing vaccines and therapies in extreme circumstances. The discussion will look forward toward the potential of the role the industry is playing during the economic rebuild in keeping Canada at the forefront of the world of biotech discovery, innovation, and entrepreneurship.
Opening chat between Minister Champagne and Andrew Casey.Panel discussion follows, featuring:Dr. Trina Racine, Associate Director, Vaccine Development, VIDODr. Thomas Madden, President and CEO, Acuitas TherapeuticsAdam Buckley, Senior Vice President Business Development, VBI Vaccines Inc
Thursday June 1010AM ET
BIOTECanada in partnership with the Government of Canada present the Canada Cafe featuring presentations by Canada's Trade Commissioner Service. This is an opportunity to enhance Canadian companies' level of knowledge and understanding of the European, North American, and Asian markets followed by a chance to network with Trade Commissioners.
Friday June 1111:00-12:00 PM ET Bio+ech Connec+ featuring Biogen
Bio+ech Connec+ is a unique forum for early-stage Canadian biotech companies to connect directly with the business development and investment leaders of multinational pharma/biotech companies. This virtual forum will include a plenary session led by senior Biogen representatives who will provide an overview of the company, its R&D priorities including its pipeline and corresponding investment priorities for the period ahead. Biogen representatives will then engage in a question and answer session.
Tuesday June 151:00-2:30 PM ET BIOTECanada, Wilson Sonsini Goodrich & Rosati present the Annual Coast to Coast Competition
Five companies from across Canada will present to a judging panel of key life science investors. The prize is a coveted presentation spot at BIOTECanada's Investor Summit held in Whistler March 2022. There will also be a unique presentation from Caroline Huang, the 2021 National Champion from Sanofi Biogenius Canada showcasing her award-winning project.
PRESENTING COMPANIES JUDGING PANELAxolotl Biosciences (BC) Lee Johnson, WSGRCytophage (MB) Florence Rozen, Le Fonds de Solidarite FTQCSTS Healthcare (ON) Parimal Nathwani, TIAPSoricimed (NB) Elizabeth Douville, AmorChem
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005990/en/
SOURCE: BIOTECanada
Nadine LuntBIOTECanada613-793-6338

Liked By
Spread the love. Be the first to like this post!
Recent VBIV News
- Annual Report (10-k) • Edgar (US Regulatory) • 03/13/2023 12:02:30 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/13/2023 12:01:23 PM
- VBI Vaccines Reports Full Year 2022 Financial Results • Business Wire • 03/13/2023 12:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/28/2023 06:03:25 PM
- VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat • Business Wire • 02/23/2023 01:00:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/15/2023 01:01:54 PM
- VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B • Business Wire • 02/15/2023 01:00:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/30/2023 10:06:14 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/30/2023 10:05:25 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/30/2023 10:04:34 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/30/2023 10:02:44 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/30/2023 10:02:44 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/30/2023 10:02:20 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/30/2022 10:01:27 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/27/2022 01:02:11 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/08/2022 01:01:18 PM
- VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults • Business Wire • 12/08/2022 01:00:00 PM
- CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal • Business Wire • 12/06/2022 02:25:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/22/2022 01:00:59 PM
- VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting • Business Wire • 11/22/2022 01:00:00 PM
- VBI Vaccines to Participate in Upcoming Investor Conferences • Business Wire • 11/14/2022 01:00:00 PM
- VBI Vaccines Announces Presentation of Data from Ongoing Phase 2a Study of VBI-1901 at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting • Business Wire • 11/11/2022 01:00:00 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/10/2022 01:01:59 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/10/2022 01:01:29 PM
- VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update • Business Wire • 11/10/2022 01:00:00 PM
Metatron Releases All-in-One Artificial Intelligence Mobile Apps for iPhone and Android • MRNJ • Mar 27, 2023 9:00 AM
Memorandum of Understanding With Miranda Water Treatment Systems and Rainmaker Worldwide Inc. Extended • RAKR • Mar 27, 2023 8:50 AM
Hollywall Entertainment Inc., (OTC:HWAL) Announces the completion of its 2021 and 2020 Audit (s) • HWAL • Mar 24, 2023 12:48 PM
Glucose Health, Inc. Fiscal 2022 Annual Report • GLUC • Mar 23, 2023 3:23 PM
Nextech3D.ai Announces Its AI-Powered SaaS Platform Toggle3D Experiences A +963% Jump in Users in 60-Days Crossing Over 1000 Users • NTAR • Mar 23, 2023 7:07 AM
Lifecycle Assessment by Benchmark Shows TMC's NORI-D Nodule Project Could Outperform Land-Based Routes of Producing Nickel, Copper and Cobalt in Almost Every Impact Category Analyzed • TMC • Mar 22, 2023 1:44 PM